1. Wadhwa, PD, Morrison, VA. Infectious complications of chronic lymphocyticleukemia. Semin Oncol 2006 Apr; 33: 240–249.
Google Scholar | Crossref | Medline2. Padgett, BL, Walker, DL, ZuRhein, GM, et al. Cultivation ofpapova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971 Jun 19; 1: 1257–1260.
Google Scholar | Medline3. Astrom, KE, Mancall, EL, Richardson Jr, EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphaticleukaemia and Hodgkin's Disease. Brain 1958 Mar; 81: 93–111.
Google Scholar | Medline4. Novero, A, Ravella, PM, Chen, Y, et al. Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014 Jan 28; 3: 4.
Google Scholar | Crossref | Medline5. Gonzalez, H, Bolgert, F, Camporo, P, et al. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999 Aug; 41: 183–186.
Google Scholar | Crossref | Medline6. Di Pauli, F, Berger, T, Walder, A, et al. Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature. J ClinVirol 2014 Aug; 60: 4247.
Google Scholar7. Lejniece, S, Murovska, M, Chapenko, S, et al. A. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocyticleukemia patient. Exp Oncol 2011 Dec; 33: 239–241.
Google Scholar | Medline8. Carson, KR, Evens, AM, Richey, EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from theResearch on adverse drug events and reports project. Blood 2009 May 14; 113: 4834–4840.
Google Scholar | Crossref | Medline9. Lutz, M, Schulze, AB, Rebber, E, et al. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Res Treat 2017 Apr; 49: 548–552.
Google Scholar | Crossref | Medline10. Bennett, CL, Berger, JR, Sartor, OP, et al. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol 2018 Jan; 180: 301–304.
Google Scholar | Crossref | Medline11. Raisch, DW, Rafi, JA, Chen, C, et al. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's Adverse event reporting system. Expert Opin Drug Saf 2016 Aug; 15: 1003–1011.
Google Scholar | Crossref | Medline12. Major, EO, Amemiya, K, Tornatore, CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992 Jan; 5: 49–73.
Google Scholar | Crossref | Medline13. Ferenczy, MW, Marshall, LJ, Nelson, CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 2012 Jul; 25: 471–506.
Google Scholar | Crossref | Medline14. Garrote, H, de la Fuente, A, Oña, R, et al. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol 2015 Mar 1; 4: 8.
Google Scholar | Crossref | Medline15. Strati, P, Uhm, JH, Kaufmann, TJ, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 2016 Apr; 101: 458–465.
Google Scholar | Crossref | Medline